RARE: Ultragenyx Pharma Expected earnings per share growth for next year

Ultragenyx Pharmaceutical is a recognized leader in the therapy of ultra-rare genetic pathologies that has earned the deep trust of patients. The GURU.Markets service provides an assessment of the expected EPS growth for the coming year, where the 105.20 mark serves as a key metric. Stable demand for unique drugs guarantees crisis resilience, while organic development through the licensing of scientific discoveries ensures long-term R&D growth.
Ultragenyx (RARE) - metric breakdowns and financial figures

This indicator reflects the aggregated consensus growth forecast for net income, allowing for an assessment of the gap between management's declarations and actual market demand. By analyzing changes in the consensus earnings per share (EPS) forecast, investors can identify the monetization potential of Ultragenyx Pharmaceutical (RARE) orphan drug status, where monopoly pricing power converts directly into financial stability and future business yield growth.